All data are based on the daily closing price as of December 24, 2024
h

Hugel

145020.KQ
191.55 USD
-1.10
-0.57%

Overview

Last close
191.55 usd
Market cap
2.11B usd
52 week high
230.24 usd
52 week low
79.27 usd
Target price
247.17 usd

Valuation

P/E
N/A
Forward P/E
19.1939
Price/Sales
9.2016
Price/Book Value
3.7672
Enterprise Value
1.82B usd
EV/Revenue
7.2802
EV/EBITDA
15.3931

Key financials

Revenue TTM
235.40M usd
Gross Profit TTM
168.70M usd
EBITDA TTM
104.61M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
899.41B usd
Net debt
N/A usd

About

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.
  • Symbol
    145020.KQ
  • Exchange
    KQ
  • Isin
    KR7145020004
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Ji-hoon Sohn
  • Headquarter
    Chuncheon-si
  • Web site
    https://www.hugel.co.kr
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top